20 Feb

Aimmune’s Peanut Allergy Drug Hits Study Goals, FDA Filing Planned

Peanuts rank among the top foods that spark allergic reactions, prompting schools to ban peanut butter sandwiches and travelers to decline airline snacks. Aimmune Therapeutics aims to help with a drug that makes people less sensitive to peanuts.

On Tuesday, Aimmune (NASDAQ: AIMT) announced that its drug met the main goals of a late-stage study, and the Brisbane, CA-based company is now planning to file for FDA approval this year. If it gets the FDA’s nod, the Aimmune drug could become the first peanut allergy treatment taken by mouth to reach the market. But some outside observers are expressing caution… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

20 Feb

Call for proposals for ERC Proof of Concept Grant

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: ERC-2017-PoCPillar: Excellent ScienceOpening Date: Deadline: Tue, 5 Sep 2017 17:00:00 (Brussels local time)Modification Date: Tue, 20 Feb 2018Latest information: Attention: Spam messages pretending to come from the Participant Portal:
Some users are reporting spam messages pretending to come from the Participant Portal in which commercial services are being promoted.
Please be on guard against messages which look identical to Participant Portal notifications but which do not stem from the Participant Portal.
We do not have control over messages claiming to be sent ‘on behalf of’ the European Commission.
On this occasion, we would also like to remind you about phishing attempts with the Participant Portal look and feel. Phishing messages typically aim to get your password, ID or bank account details under a fake pretext, for instance inviting you to update your information online.
Please note that the Participant Portal will never ask you to send important personal and financial data via email.
Your first action against phishing is to be vigilant. Protect yourself by keeping the following advices in mind: http://ec.europa.eu/research/participants/portal/desktop/en/support/about.html

20 Feb

Under the Microscope We Place Shares of Puma Biotechnology, Inc. (NYSE:PBYI) and Dorman …

Dedicated investors are constantly on the lookout for a bargain when it comes to stock picking. As of late, investors have been taking notice of Puma Biotechnology, Inc. (NYSE:PBYI) shares. During recent trading, shares saw a move of -1.54% hitting a price of $67.05. Here we’ll take a quick glance at …

19 Feb

Call for proposals for ERC Consolidator Grant

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: ERC-2018-COGPillar: Excellent ScienceOpening Date: Deadline: Thu, 15 Feb 2018 17:00:00 (Brussels local time)Modification Date: Mon, 19 Feb 2018Latest information: The ERC-2018-COG call closed on 15 February 2018. A total of 2389 proposals were submitted in response to the ERC 2018 Consolidator Grant Call (ERC-2018-COG). The number of proposals for each domain is shown below:

• Physical Sciences & Engineering (Panels: PE1 – PE10) 1051
• Life Sciences (Panels: LS1 – LS9) 704
• Social Sciences & Humanities (Panels: SH1 – SH6) 634

The next call ERC-2019-COG is planned to be published and be opened for submission on the Participant Portal in October 2018.

19 Feb

New Infographic: Balancing Need for Innovation with Competition

It is an underreported fact that the time it takes for a generic medicine to come to market has remained steady at approximately 13.5 years for over two decades. And, once entering the market, generics are acquiring greater market share, faster than ever before.

That’s why BIO is releasing its a new infographic, which highlights the highly successful effects of the Hatch-Waxman Act and the role it has played in balancing innovation and competition, as Congress intended.

BIO supports continued FDA initiatives to improve first-cycle generic approval rates, as this problem is the biggest barrier to more generic entry.

 

 

 

18 Feb

50000 Shares in Puma Biotechnology Inc (PBYI) Acquired by Artal Group SA

Puma Biotechnology logo Artal Group S.A. bought a new position in shares of Puma Biotechnology Inc (NASDAQ:PBYI) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 50,000 shares of the biopharmaceutical company’s stock, …

17 Feb

FET-Open – Novel ideas for radically new technologies

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-FETOPEN-2016-2017Pillar: Excellent ScienceOpening Date: Deadline: Wed, 11 May 2016 17:00:00 (Brussels local time)Modification Date: Sat, 17 Feb 2018Latest information:
An overview of the evaluation results (flash call info) for the topics FETOPEN-01-2016-2017and FETOPEN-04-2016-2017 that closed on 27 September 2017 is now available under the ‘Topic conditions & documents’ section on each topic page.

16 Feb

LGC Acquires Lucigen, Marking Latest Exit for CEO Ralph Kauten

Chalk up another exit for Ralph Kauten.

Kauten, one of Wisconsin’s more successful biotech entrepreneurs, is chairman and CEO of Lucigen, a Middleton, WI-based vendor of life sciences research tools that on Friday said it has been acquired by LGC.

LGC, which is based in the U.K. and says it has 2,300 employees, provides testing services, reference materials, and ancillary products to organizations in the diagnostic and drug development industries, among others.

LGC did not say how much it’s buying Lucigen for or provide specific financial terms of the acquisition in its announcement of the deal.

Lucigen was founded… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

16 Feb

Gene-Editing: How Do We Move Towards Acceptance

As biotechnology continues to drive advancement in the way we grow and consume food, consumer skepticism around biotechnology remains steady. As I alluded to in Science Over Fiction: GMOS for Public Good, consumer skepticism is largely derived from misconceptions around the science behind biotechnology.

For example, take the following survey results as noted in a piece from Agri-Pulse titled Are consumer ready to accept gene editing?

A Michigan State University Food Literacy and Engagement Poll asked 1,059 U.S. adults last summer, for example, if this statement is true: “Genetically modified foods have genes and non-genetically modified foods do not,” and 37 percent agreed, showing that many people just don’t know what genes or GMOs are.

More concerning, however, are the results from another survey mentioned in the piece, in which Americans were asked if they want mandatory labeling of DNA in foods.

The result: 80 percent said yes. Obviously, those respondents did not understand that DNA (deoxyribonucleic acid) is an essential part of all living organisms – organic, non-GMO or GMO.

What’s intriguing, however, is the fact that most people (59 percent) “expressed at least some support for human genome editing to treat human medical conditions or restore health.”

This mix of opinions affirm the notion that many perceptions about biotechnology and food are based on misunderstanding and fear. As we touched on in When Food Companies Use Lies (and Children!) to Fool Consumers, the organic industry has found success in generating fear among the public when it comes to biotechnology in food. But, when consumers start to think about biotechnology’s benefit to their own health, perceptions seem to change.

Gene editing carries many of the same promises that gene modification does, but will consumers fall victim to fearmongering or will they begin to understand the science behind it and accept this promising technology?

Read the full piece here.

16 Feb

BUILDING A LOW-CARBON, CLIMATE RESILIENT FUTURE: SECURE, CLEAN AND EFFICIENT ENERGY

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-LC-SC3-2018-2019-2020Pillar: Societal ChallengesPlanned Opening Date: Deadline: Tue, 5 Feb 2019 17:00:00 (Brussels local time)Modification Date: Fri, 16 Feb 2018Latest information: The Frequently Asked Questions for topic LC-SC3-EE-6-2018-2019-2020 can be accessed here.